Répertoire de l'Université Alfonso X el Sabio

Pressure Support Ventilation and Volume Guarantee During Surfactant Therapy

Afficher la notice abrégée

APA

López Escobar, Alejandro & Llana Martín, I. & Touza Pol, P. & Bugarini, S. & Cantón, C. & Fernández Díaz, M. & Jimeno Ruiz, S. & Benedit Gómez, M. .Pressure Support Ventilation and Volume Guarantee During Surfactant Therapy.

ISO 690

López Escobar, Alejandro & Llana Martín, I. & Touza Pol, P. & Bugarini, S. & Cantón, C. & Fernández Díaz, M. & Jimeno Ruiz, S. & Benedit Gómez, M.. Pressure Support Ventilation and Volume Guarantee During Surfactant Therapy.

https://hdl.handle.net/20.500.12080/44599
dc.contributor.author López Escobar, Alejandro
dc.contributor.author Llana Martín, I.
dc.contributor.author Touza Pol, P.
dc.contributor.author Bugarini, S.
dc.contributor.author Cantón, C.
dc.contributor.author Fernández Díaz, M.
dc.contributor.author Jimeno Ruiz, S.
dc.contributor.author Benedit Gómez, M.
dc.date.accessioned 2024-10-18T15:31:00Z
dc.date.available 2024-10-18T15:31:00Z
dc.date.created 2010
dc.identifier.uri https://hdl.handle.net/20.500.12080/44599
dc.description.abstract Introduction: Intratracheal administration of surfactant is a very common procedure, however it is not well standarised. Objectives: Complications found during surfactant therapy in Pressure-Support-Ventilation and Volume- Guarantee (PSV/VG) from Dräger-Babylog-8000. Patients and Methods: Descriptive and prospective study in newborns with respiratory distress syndrome to whom surfactant was given in our Neonatal- Intensive-Care-Unit during the period of study: 2008- 2009. Curosurf was administrated through a duallumen- endotracheal-tube. Ventilatory mode: PSV/ VG. Ventilator parameters and vital signs before, during and after surfactant administration were monitorised (5 and 10 minutes). Results: 14 doses of surfactant were given to 12 infants (3 of them same patient). 11 of them were preterm (32w, 1892,15gr). 6 weight less than 1500 g. Surfactant was administrated at 21,7h of life. No changes in cardiac rate or oxygen saturation were found during the procedure. Significant differences between the FiO2 before and 5minutes (53,5-32,5%) p< 0.009 and 10minutes (53,5-28,35%) p< 0,043 after the administration of surfactant were recorded. There was no significant difference regarding cardiac rate. Low blood pressure was not detected at any time after surfactant. None of the complications described in literature in relation to the administration of surfactant (pulmonary bleeding, air escape, apnoea, endotracheal tube obstruction) occurred in any of our cases. Discussion: Surfactant therapy disminishes the requirements of supplementary oxygen. According to our data, PSV/VG could be a safe option for the administration of intratracheal surfactant as we have not recorded complications during this procedure. However more studies with a higher number of patients are needed to confirm these findings. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.source Pediatric Research es_ES
dc.title Pressure Support Ventilation and Volume Guarantee During Surfactant Therapy es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/closedAccess es_ES
dc.identifier.location N/A es_ES


Fichier(s) constituant ce document

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

CC-BY Excepté là où spécifié autrement, la license de ce document est décrite en tant que CC-BY

Chercher dans le dépôt


Parcourir

Mon compte

Social Media